U.S. Medical Affairs
U.S. MEDICAL AFFAIRS
U.S. Medical Affairs maintains valuable relationships with the scientific and medical community, supports quality medical education and invests in research to benefit patients, healthcare professionals, and society as a whole.
Medical Science Liaisons
Medical Science Liaisons (MSLs) facilitate communication between Lupin and healthcare professionals in responding to medical and scientific inquiries, engaging in scientific exchange, offering educational support, and identifying educational and research gaps. They work throughout a product’s lifecycle, help to ensure that products are utilized effectively, serve as scientific peers and resources within the medical community, and are scientific experts to internal colleagues at Lupin.
Medical Education Grants (MEG)
Lupin supports MEG activities in our therapeutic areas of expertise to maintain, develop, or increase the knowledge, skills, and professional performance of healthcare professionals. Requests for support must be submitted through the online application form and must include a summary of your request on institutional letterhead, an IRS W9 form, proof of accreditation if applicable, a detailed budget, and a program agenda or brochure. Requests for funding of a MEG will be reviewed generally within 30 days and we will contact you to inform you of our decision.
Medical Education Grants (MEG)
Lupin supports MEG activities in our therapeutic areas of expertise to maintain, develop, or increase the knowledge, skills, and professional performance of healthcare professionals. Requests for support must be submitted through the online application form and must include a summary of your request on institutional letterhead, an IRS W9 form, proof of accreditation if applicable, a detailed budget, and a program agenda or brochure. Requests for funding of a MEG will be reviewed generally within 30 days and we will contact you to inform you of our decision.
Investigator-Initiated Research (IIR)
Lupin considers requests for support of IIR involving our marketed products and/or in our therapeutic areas of expertise. Lupin may decide to provide support in the form of funding and/or the provision of a drug. Lupin receives requests for IIR support regularly and will evaluate proposals based on their scientific merit, clinical relevance, and how they address unmet medical needs. Requests for support must be submitted through the online application form and must include the protocol, principal investigators’ CV, and a budget summary. Following submission of your application, a thorough review in accordance with all established policies and guidelines will occur generally within 30 days. We will then contact you to inform you of our decision, or to request additional information.
Publications
Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017 Dec;217(6):678.e1-678.e9.
Hillier SL, Nyirjesy P, Waldbaum AS, Schwebke JR, Morgan FG, Adetoro NA, Braun CJ. Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial. Obstet Gynecol. 2017 Aug;130(2):379-386.
Chavoustie SE, Gersten JK, Samuel MJ, Schwebke JR. A Phase 3, Multicenter, Prospective, Open-Label Study to Evaluate the Safety of a Single Dose of Secnidazole 2 g for the Treatment of Women and Postmenarchal Adolescent Girls with Bacterial Vaginosis. J Womens Health (Larchmt). 2018 Apr;27(4):492-497.
Nyirjesy P, Schwebke JR. Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment. Future Microbiol. 2018 Apr;13:507-524.
Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study Christina A. Muzny, Jane R. Schwebke, Paul Nyirjesy, Gregory Kaufman, Leandro A. Mena, Gweneth B. Lazenby, Olivia T. Van Gerwen, Keonte J. Graves, Janeen Arbuckle, Belvia A. Carter, Connette P. McMahon, Scott Eder, Jackie Shaw, Brajesh Pandey, and Steven E. Chavoustie
Click here for MAJOR ARTICLE on Trichomoniasis.
